The WIRB-Copernicus Group’s (WCG) Clinical Services Division has acquired Analgesic Solutions, LLC, a developer of new pain medications and supporter of clinical trials in which pain is an indicator of an underlying condition. Analgesic Solutions joins WCG clinical services which facilitate the conduct of clinical trials. WCG’s newest addition focuses on increasing assay sensitivity in clinical trials through consulting, innovative tools, data science, technology and specialized training. 

“We are delighted to welcome Dr. Nathaniel Katz, the founder and chief scientist of Analgesic Solutions, and his extraordinary team of clinicians and scientists to WCG,” said Donald A. Deieso, PhD, Executive Chairman and CEO of WCG. “The intense public focus on developing alternatives to opioids for use in pain management, as well the organization’s deep understanding of patients’ subjective responses to pain, has made Analgesic Solutions one of the most sought-after solution providers in clinical research.”

“We are very pleased to join WCG – an organization which shares our values, our purpose, and above all, our commitment to scientific integrity,” said Nathaniel Katz, MD, MS, Founder and Chief Science Officer, Analgesic Solutions. “What excites us most about collaborating with our colleagues at WCG is helping biopharmaceutical sponsors to accelerate the development of pain-reducing therapies by improving the quality of clinical research in this area.”

Analgesic Solutions advises research sponsors on protocol design and development, regulatory and FDA submissions, and provides knowledge-based solutions that inform the conduct of clinical trials in which the measurement of pain is an endpoint or significant component. The company also provides central statistical monitoring and interventions to ensure that data produced and collected during trials are reliable and accurate with the goal of proactively protecting study outcomes.